Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a global, commercial-stage biopharmaceutical company specializing in the development and commercialization of targeted radiopharmaceuticals for oncology. Headquartered in Melbourne, Australia, Telix focuses on precision medicine, with a pipeline centered on theranostic solutions—combining diagnostic imaging and targeted radiotherapy for cancers such as prostate, kidney, brain, and sarcoma. The company operates through three core units: Therapeutics, Precision Medicine, and Manufacturing Solutions, supporting both clinical development and global commercial supply. Telix’s lead product candidates include TLX591 for advanced prostate cancer and TLX250 for metastatic kidney cancer, both in late-stage clinical trials. The company maintains a significant international footprint, with operations in the United States, Europe, and Japan, and has invested in advanced manufacturing infrastructure to support global demand. Telix Pharmaceuticals Limited is listed on the CHI-X Market Australia - Limit Venue, providing access to investors seeking exposure to innovative oncology-focused biotech assets.